The Medical Letter on Drugs and Therapeutics
Ryanodex - A New Dantrolene Formulation for Malignant Hyperthermia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new IV formulation of dantrolene (Ryanodex – Eagle) for prevention and treatment of malignant hyperthermia in adults and children. The new formulation requires fewer vials, less fluid volume, and less time for preparation and administration than other available IV dantrolene products (Dantrium, Revonto).

THE DISORDER — Malignant hyperthermia is a rare hypercatabolic reaction characterized by uncontrolled release of calcium ions in skeletal muscle cells that most often occurs in genetically predisposed patients who are exposed to certain inhaled anesthetics or the muscle relaxant succinylcholine. Dantrolene, which decreases calcium release from the sarcoplasmic reticulum, has been a drug of choice for treatment of malignant hyperthermia for many years.1

THE NEW FORMULATION — Ryanodex is available ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ryanodex - A New Dantrolene Formulation for Malignant Hyperthermia
Article code: 1472c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian